Summary
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak
NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of Ebola virus that has prompted the World Health Organisation to declare a global health emergency. The WHO designated the outbreak in eastern Democratic Republic of Congo a Public Health Emergency of International Concern on 17 May, after the virus killed at least 88 people across 336 suspected cases, with two infections also confirmed in neighbouring Uganda.
NanoViricides to raise $2M in registered direct offering
NanoViricides (NYSE-A:NNVC) said it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately $2 million in a registered direct offering. Under the terms of the agreement, the company will sell just over 1.3 million common shares, or pre-funded warrants in lieu thereof, together with accompanying warrants to purchase an equal number of common shares.
NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak
NanoViricides (NYSE-A:NNVC) is pointing to its lead drug candidate NV-387 as a potential solution to a critical gap in infectious disease preparedness, as a deadly hantavirus outbreak aboard a cruise ship triggers a costly global containment effort. The Connecticut-based clinical-stage company said NV-387 has completed Phase I clinical trials for safety and tolerability in healthy volunteers and has shown effectiveness against multiple virus families in lethal animal models, including coronaviruses, RSV, influenza, monkeypox and measles, tested via the same respiratory route through which Andes hantavirus spreads.
Nanoviricides Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 35 | $31.85 | $60.55 | $28.7 | 90.11% |
| SE Sima Elimelech Activest Wealth Management | 1,000 | $1,720 | $1,770 | $50 | 2.91% |
 Katherine Saltonstall Sandy Cove Advisors LLC | 10,000 | $9,100 | $17,200 | $8,100 | 89.01% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $0.91 | $1.83 | $0.92 | 101.1% |
 Christopher C. Powers Farther Finance Advisors, LLC | 500 | $477 | $875 | $398 | 83.44% |
Nanoviricides Inc. (NNVC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nanoviricides Inc. ever had a stock split?
Nanoviricides Inc. Profile
| Biotechnology Industry | Healthcare Sector | Anil R. Diwan CEO | AMEX Exchange | 630087302 CUSIP |
| US Country | 7 Employees | - Last Dividend | 24 Sep 2019 Last Split | 26 Oct 2005 IPO Date |
Overview
NanoViricides, Inc. is a pioneering clinical stage nano-biopharmaceutical company focused on the discovery, development, and commercialization of novel drugs for the treatment of viral infections. Founded in 2005 and based in Shelton, Connecticut, the company leverages its proprietary nanoviricide® technology to craft innovative therapies aimed at various viral diseases. This technology employs biomimetic strategies to create drugs that mimic natural virus-binding mechanisms, allowing for targeted delivery of antiviral payloads directly into infected cells while sparing healthy ones. Through its advanced research and clinical trials, NanoViricides aims to bring new solutions to market that address unmet medical needs in the management of viral infections.
Products and Services
The following are the key products and services developed by NanoViricides, Inc.:
- NV-CoV-2, Nanoviricide Drug
This drug is currently undergoing phase 1a/1b clinical trials for the treatment of COVID-19. It represents the company's commitment to addressing the global pandemic by harnessing their nanoviricide technology to target and neutralize the virus.
- NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies
Designed specifically for pediatric cases, these semi-solid fixed-dose forms are in phase 1a/1b human clinical trials. They allow for body-weight-based dose titration, offering a potentially safer and more effective treatment option for children suffering from COVID-19.
- NV-CoV-2 Solution for Injection, Infusion, and Inhalation
This versatile formulation is aimed at treating severe cases of COVID-19 that have not yet required hospitalization. It can be administered as an injection or delivered directly into the lungs using a nebulizer. This method seeks to directly target the primary site of infection by many respiratory viruses, potentially offering a significant advantage in treating diseases that can lead to severe pneumonia.
- Nanoviricide Biomimetic Platform Technology
The cornerstone of NanoViricides' offerings, this platform technology is designed to carefully mimic the envelope of virus particles. It facilitates the delivery of antiviral drugs directly into infected cells, disrupting the virus's replication cycle with minimal toxicity to healthy cells. This technology represents a broad-spectrum approach capable of targeting a variety of enveloped viral infections beyond COVID-19, including influenza, RSV, and more.
